

Balloon-TACE Efficacy

Since the first particle-based tumor embolization in the early 1970's, embolization agents have improved dramatically. Over the same period, development of devices capable of delivering complete tumor fill have been lacking, even though tumor fill is the single most important factor in achieving a CR^{1,2}. Sniper® is a superselective delivery device that improves tumor fill and associated complete response at the first procedure. **The efficacy of Balloon-TACE (B-TACE) is remarkable.**

On Average, Balloon-TACE Improves CR on the First Procedure by 1.5X
 Eight Clinical Studies with 941 Patients are Presented Below

2-Arm Studies, Balloon vs Standard Microcatheter

Golfieri, 2021³ 📄

Multi Center, 2-Arm Retrospective
 530 patients (p = 0.026)
 B-cTACE/B- DEB-TACE Improve CR by **40%**
 Retreatment Rate at 6 months:
 B-TACE 10%, Standard Micro 22% (**120% Better**)

Irie, 2016⁴ 📄

2-Arm Retrospective
 77 patients, p = 0.016
 B-cTACE Improves CR by **37%**
 100% Objective Response
 5 Year Survival Improved by **53%**

Arai, 2015⁵ 📄


2-Arm Retrospective,
 97 patients (p < 0.05)
 B-cTACE Improves CR by **39%**
 Disease Progression Reduced from **25% to 4%**

Lucatelli, 2021⁶ 📄

2-Arm Retrospective
 97 patients (p < 0.05)
 B-DEB-TACE Improves CR by **39%**

Ogawa, 2016⁷ 📄

2-Arm Retrospective
 61 patients (p = 0.035)
 B-cTACE Improves CR by **81%**



1-Arm Studies

Lee, Madoff, 2021 📄

1-Arm Retrospective, 31 patients
 74% CR, 95% OR (p < 0.05)
100% Disease Control

Lucatelli, 2019 📄

1-Arm Retrospective B-DEB-TACE, 22 patients
 44% CR (p < 0.05)
100% Objective Response

Goldman, Fischman, 2018 📄

1-Arm Retrospective, 26 patients
 60% CR (p < 0.05)
100% Disease Control

Summary

Eight B-TACE Clinical Studies, including almost 1000 patients from the US, Japan & Italy are **consistent in demonstrating a remarkable rate of complete response at the first procedure that is 1.5 times better than a standard microcatheter.** This is prognostic for a > 50% improvement in 5-year survival⁸ which was also demonstrated by [Irie, 2016](#)⁴.

References

1. Kim DY, Ryu HJ, Choi JY, Park JY, Lee DY, Kim BK, Ahn SH, Chon CY, Han KH. Radiological response predicts survival following transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. *Alimentary Pharmacology and Therapeutics* (2012) 35:1343-1350.
2. Miyayama S, Matsui O, Yamashiro M, Ryu Y, Kaito K, Ozaki K, Takeda T, Yoneda N, Notsumata K, Toya D, Tanaka N, Mitsui T. Ultrasensitive transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between tumor recurrence and visualization of the portal vein with iodized oil (2007).
3. Golfieri R, Bezzi M, Verset G, Fucilli F, Mosconi C, Cappelli A. *Cardio Intervent Radiol* (2021) <https://doi.org/10.1007/s00270-021-02805-5>.
4. Irie T, Kuramochi M, Kamoshida T, Takahashi N. Selective balloon-occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules: retrospective comparison with conventional super-selective TACE. *Hepatology Research* (2016) 46:209-214.
5. Arai H, Abe T, Takayama H, et al. Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma. *Hepatology Research* (2015) 45: 663-666.
6. Lucatelli P, De Rubeis G, Rocco B, Basilico F, Cannavale A, et al. Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study. *BMC Gastroenterology* (2021) 21:55 1-9.
7. Ogawa M, Takayasu K, Hirayama M, et al. Efficacy of a microballoon catheter in transarterial chemoembolization using miriplatin, a lipophilic anticancer drug: short-term results. *Hepatology Research* (2016) 46: E60-69.
8. Kim BK, Kim BU, Kim KA, et al. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. *Journal of Hepatology* (2015) 62:1304-1310.